Y90 radioembolization followed by intravenous Nivolumab for advanced hepatocellular carcinoma

To evaluate the efficacy of combination therapy with ICI and RT in patients, a Phase II trial (CA209-678) was conducted to investigate the efficacy and safety of Y90-RE followed by nivolumab in patients with advanced HCC (NCT03033446, n = 36). Interestingly, the ORR was found to be 30.6% in all patients and 43.5% when restricted to patients with only intrahepatic tumors, suggesting possible synergism between Y90-RE and ICI. Here we present whole exome sequencing (WES) and RNA-seq data for 33 patients treated with Y90 radioembolization followed with Nivolumab.EGA study EGAS00001006834

为评估免疫检查点抑制剂（Immune Checkpoint Inhibitor, ICI）联合放疗（Radiation Therapy, RT）的临床疗效，本研究开展了一项II期临床试验（CA209-678），针对晚期肝细胞癌（Hepatocellular Carcinoma, HCC）患者探究钇90放射栓塞术（Yttrium-90 Radioembolization, Y90-RE）序贯纳武利尤单抗（nivolumab）的疗效与安全性，该试验编号为NCT03033446，共纳入36例受试者。值得注意的是，所有受试者的客观缓解率（Objective Response Rate, ORR）为30.6%；若仅纳入仅存在肝内肿瘤的患者，客观缓解率可达43.5%，这提示Y90-RE与ICI之间可能存在协同效应。本研究公开了33例接受Y90放射栓塞术序贯纳武利尤单抗治疗的患者的全外显子组测序（Whole Exome Sequencing, WES）与RNA测序（RNA-seq）数据，相关数据集存档于欧洲基因组学档案（European Genome-phenome Archive, EGA），存档编号为EGAS00001006834。